Compare TPL & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPL | EXAS |
|---|---|---|
| Founded | 1888 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6B | 19.3B |
| IPO Year | N/A | N/A |
| Metric | TPL | EXAS |
|---|---|---|
| Price | $296.27 | $101.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | ★ $350.00 | $77.94 |
| AVG Volume (30 Days) | 452.8K | ★ 3.7M |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 6.20 | N/A |
| EPS | ★ 6.90 | N/A |
| Revenue | $772,395,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $10.07 | $19.40 |
| Revenue Next Year | $19.21 | $13.51 |
| P/E Ratio | $43.18 | ★ N/A |
| Revenue Growth | 12.48 | ★ 14.47 |
| 52 Week Low | $269.23 | $38.81 |
| 52 Week High | $487.59 | $102.66 |
| Indicator | TPL | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 17.16 | 80.65 |
| Support Level | $280.95 | $101.55 |
| Resistance Level | $298.00 | $102.05 |
| Average True Range (ATR) | 20.39 | 0.38 |
| MACD | -43.33 | -1.16 |
| Stochastic Oscillator | 2.50 | 31.17 |
Texas Pacific Land Corp is mainly engaged in the sales and leases of land owned, retaining oil and gas royalties, and the overall management of the land owned. It operates its business in two reportable segments; Land and Resource Management and Water Service and Operations. The Land and Resource Management segment focuses on managing surface acres of land and its oil and gas royalty interests, principally concentrated in the Permian Basin. The Water Services and Operations segment encompasses the business of providing full-service water offerings to operators, produced-water treatment, infrastructure development, and disposal solutions. The company generates the majority of its revenue from the Land and Resource Management segment.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.